Visar o sistema endocanabinóide para tratar melanoma cutâneo: uma revisão sistemática

• Autor(a) principal: Nuno Miguel Ferreira da Silva Marinho Falcão
• Data de Publicação: 2020
• Tipo de documento: Dissertação
• Idioma: eng
• Título da fonte: Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)
• Texto Completo: https://hdl.handle.net/10216/128856
• topic: Ciências médicas e da saúde; Medical and Health sciences

Introduction: Skin melanoma is a malignant neoplasm of melanocytes and is the deadliest of all skin cancers. It is a highly metastatic neoplasia, for which conventional therapy is often ineffective. The endocannabinoid system is implicated in proliferation, differentiation and survival of skin melanocytes. In this study, we collect published data regarding the role of cannabinoids, cannabinoid 1 (CB1) and cannabinoid 2 (CB2) receptors in the treatment of skin melanoma. Methods: PRISMA guidelines were followed for a systematic literature review of published data accessing the role of cannabinoids on melanoma treatment. A PUBMED search was conducted, for published studies until January 2020, using the queries: "Cannabinoid AND Melanoma", "CB1 AND Melanoma" and "CB2 AND Melanoma". Results: Of the 116 articles retrieved, 11 were included in this review. Conclusion: CB1 and CB2 activation is responsible for inhibiting melanoma cell growth in vitro, mostly by cell-cycle arrest and induction of apoptosis. Membrane lipid rafts and GPR55 are also involved in cannabinoid action. Cannabinoids decrease tumor growth and metastasis in vivo. The endocannabinoid system may be a relevant target of melanoma treatment. Key words: Endocannabinoid system, cannabinoid, melanoma, CB1, CB2.